CD133, CD47, and PD-L1 expression in ovarian high-grade serous carcinoma and its association with metastatic disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20221001006

Enrollment

Registered

2022-10-01

Start date

2021-05-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-grade serous ovarian carcinoma CD133 expression CD47 expression PD-L1 expression

Interventions

metastatic high-grade serous ovarian carcinoma samples ,non-metastatic high-grade serous ovarian carcinoma samples

Basic Science,Basic Science

metastatic-HGSC ,nonmetastatic-HGSC

Eligibility

Sex/Gender

Female

Age

17 Years to 70 Years

Inclusion criteria

Inclusion criteria: All samples were taken from patients with high-grade serous ovarian carcinoma

Exclusion criteria

Exclusion criteria: The paraffin block preparation of high-grade serous ovarian carcinoma tissue damaged during CD133, CD47, and PD-L1 immunohistochemical examination.

Design outcomes

Primary

Measure	Time frame
Immunohistochemistry examination at 12 months after end of the surgery expression of CD133, CD47, and PDL-1	—

Secondary

Measure	Time frame
Characteristics data at the time of surgery age (years)	—

Countries

Indonesia

Contacts

Public ContactRina Masadah

Hasanuddin University

r.masadah@med.unhas.ac.id062411586010

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026